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Abstract
Background: Brain atrophy is a well-accepted imaging biomarker of multiple sclerosis (MS) that partially correlates with
both physical disability and cognitive impairment.
Methodology/Principal Findings: Based on MRI scans of 60 MS cases and 37 healthy volunteers, we measured the volumes
of white matter (WM) lesions, cortical gray matter (GM), cerebral WM, caudate nucleus, putamen, thalamus, ventricles, and
brainstem using a validated and completely automated segmentation method. We correlated these volumes with the
Expanded Disability Status Scale (EDSS), MS Severity Scale (MSSS), MS Functional Composite (MSFC), and quantitative
measures of ankle strength and toe sensation. Normalized volumes of both cortical and subcortical GM structures were
abnormally low in the MS group, whereas no abnormality was found in the volume of the cerebral WM. High physical
disability was associated with low cerebral WM, thalamus, and brainstem volumes (partial correlation coefficients ,0.3–0.4)
but not with low cortical GM volume. Thalamus volumes were inversely correlated with lesion load (r=20.36, p,0.005).
Conclusion: The GM is atrophic in MS. Although lower WM volume is associated with greater disability, as might be
expected, WM volume was on average in the normal range. This paradoxical result might be explained by the presence of
coexisting pathological processes, such as tissue damage and repair, that cause both atrophy and hypertrophy and that
underlie the observed disability.
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Introduction
Multiple sclerosis (MS) causes multifocal white matter (WM)
lesions that are easily visible on MRI and that are characterized by
a varied array of pathologic processes, including inflammation,
demyelination, remyelination, edema, axonal damage, and gliosis
[1]. All of these processes can cause substantial changes in tissue
volume. Multifocal gray matter (GM) lesions are present as well,
but they are less conspicuous on MRI due to smaller increases in
water content; indeed, on conventional MRI, GM involvement is
mostly characterized by volume loss [2–4] that begins early in the
disease course [5,6]. GM volume loss includes both cortical
thinning [7,8] and subcortical atrophy [9–12]. A central open
question is the extent to which WM and GM damage interact with
one another and contribute to disability in MS [13].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37049Disability in MS is commonly assessed via the Expanded
Disability Status Scale (EDSS) and the MS Functional Composite
(MSFC) [14]; the MS Severity Score (MSSS) [15] is another useful
measure. The relationships between each of these measures and
volumes of lesions and/or individual brain structures have been
studied previously. For example, there is an inverse correlation
between EDSS and normalized measures of brain volume [6,16]
as well as volumes of WM and GM, both globally [2,17,18] and
regionally [8,19]. However, associations between volumetric
abnormalities and measures of disability in individual limbs, such
as ankle dorsiflexion strength and great-toe vibration thresholds,
have been poorly characterized if at all.
Missing from the literature is a cross-sectional characterization
of brain structure volumes and their association with a wide range
of disability scores in a single representative cohort. Specifically,
studies of subcortical GM structures have been limited either to a
few structures at a time [9–11] or to a few disability scores [12].
Moreover, the relationship of brainstem atrophy to disability has
not been completely characterized [12,20,21]. This is important
because in MS the spinal cord is an important substrate of
disability, and brainstem and spinal cord volumes are correlated
[21].
To address this gap in the literature, the current study
investigates brain structure volumes (including cortical and
subcortical GM structures, cerebral WM, CSF, and brainstem)
and volumes of WM lesions, as well as the relationship between
brain volumetric abnormalities and strength, cognitive, and
sensory impairment measures. The study group is a representative
sample of MS cases (including all three major MS subtypes) at a
tertiary referral center. The cases represent a wide spectrum of
disability, age, and disease duration. Results from MS cases are
compared with those from a matched group of healthy volunteers.
Scans were analyzed using Lesion-TOADS, our previously
described, freely available software package that segments the
brain into its major structures while simultaneously delineating
WM lesions [22]. The major advantage of Lesion-TOADS is that
it provides a comprehensive account of brain structure volumes
with no manual interaction, making it particularly useful for large-
scale studies.
Materials and Methods
Ethics Statement
Protocols were approved by the Institutional Review Boards at
the Johns Hopkins University School of Medicine and the F.M.
Kirby Research Center for Functional Brain Imaging at the
Kennedy Krieger Institute. Written, informed consent was
obtained from all participants.
Participants
The study group consisted of 37 healthy volunteers (22 women)
with a mean age of 37 years (range: 23–63) and 60 MS cases (45
women) with a mean age of 43 years (range: 20–68) and mean
disease duration of 8 years (range: 0–30). There were 43 cases of
relapsing remitting (RRMS), 9 cases of secondary progressive MS
(SPMS), and 8 cases of primary progressive MS (PPMS). MS cases
were referred by treating neurologists in the Johns Hopkins MS
Center. We did not enroll prospective participants who had
additional neurological diagnoses that could cause abnormalities
on brain MRI. 53 MS cases were taking disease-modifying therapy
at the time of the study; the others were untreated at the time of
scanning. We collected clinical data at the Johns Hopkins
University and MRI scans at the F. M. Kirby Research Center
for Functional Brain Imaging at the affiliated Kennedy Krieger
Institute.
Impairment measures
We performed the MSFC and EDSS within 30 days of the MRI
scans on all the MS cases. We used the protocol prescribed in the
MSFC Administration and Scoring Manual [23] to administer the
individual MSFC components (9-hole peg test, PASAT-3, and
timed 25-foot walk) and to calculate the final summary z-scores.
For all statistical analyses, we averaged the 9-hole peg-test times
across the dominant and non-dominant hands. We also computed
the MSSS score, which relates scores on the EDSS to the
distribution of disability in patients with comparable disease
durations [15]. We assessed vibration sensation and ankle
dorsiflexion strength within a week of the MRI scans to quantify
sensorimotor dysfunction in a subset of 56 subjects from the MS
cohort (41 RRMS, 8 SPMS, 7 PPMS). We quantified vibration
sensation thresholds for both great toes using the Vibratron II
device (Physitemp, Huron, NJ) [24]. For this test, each subject was
evaluated using a two-alternative forced choice procedure [24].
We quantified ankle dorsiflexion strength using a Microfet2 hand-
held dynamometer (Hoggan Health Industries, West Jordan, UT)
[25]. For this test, the average of two maximal efforts for each
ankle was calculated and recorded. For subsequent analysis, we
selected the value obtained from the side with the poorer sensory
or motor score [26]. Table 1 shows the impairment statistics in the
MS cohort. We did not test for impairments in the healthy
volunteers.
MRI protocol and image analysis
We acquired all images on a 3 tesla scanner (Intera, Philips
Medical Systems). We used 2 axial, whole-brain sequences without
gaps for this study: multislice, T2-weighted fluid-attenuated
inversion recovery (FLAIR; acquired resolution: 0.860.862.2 or
0.860.864.4 mm; TE: 68 ms; TR: 11 s; TI: 2.8 s; SENSE factor:
2; averages: 1); and 3D magnetization-prepared rapid acquisition
of gradient echoes (MPRAGE; acquired resolution:
1.161.161.1 mm; TE: 6 ms; TR: ,10 ms; TI: 835 ms; flip
angle: 8 deg; SENSE factor: 2; averages: 1).
We analyzed the images with the TOADS-CRUISE software
package (http://www.nitrc.org/projects/toads-cruise). Our previ-
ously published and validated segmentation method, Lesion-
TOADS [22], segmented the brain into its component structures
while simultaneously delineating the lesions. Lesion-TOADS
combines the intensity information from MPRAGE and FLAIR
images with statistical and topological atlases to yield the locations
and volumes of FLAIR-hyperintense WM lesions, sulcal CSF,
ventricular CSF, cortical GM, total cerebral WM (including
lesions), cerebellar GM, cerebellar WM, putamen, caudate,
thalamus, and brainstem (Fig. 1). Before applying Lesion-TOADS,
we first removed the skull and extracranial tissues, again using an
automated method [27] based on the MPRAGE scan and then
applied the resulting brain-and-CSF mask to the coregistered
FLAIR scan. Next, we rigidly registered the stripped MPRAGE
scans to a single image atlas (‘‘JHU_MNI_SS_T1’’) that is
available for download (http://www.mristudio.org). This atlas,
which contains 1 mm isotropic voxels in a field-of-view of
18162176181 mm, has been registered to the standard Montreal
Neurological Institute-152 atlas. The FLAIR images were also
transformed to this space. As the imaging field of view affects the
measurement of brainstem volume, we cropped all the images on a
certain location in the MNI space in the inferior part of the brain
(z=25). After manual review of the segmentation results by an
experienced observer (DSR), we identified 12 MS cases with low
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Lesion-TOADS procedure when run with the default settings. In
these cases, we modified the default settings by decreasing the
parameter controlling the intensity variance of lesions, which
resulted in successful segmentation. Only four cases required
manual editing of the lesion masks.
After segmenting brain structures and lesions, we computed the
cerebral volume fraction (CVF) by normalizing the sum of the
volumes of all brain structures except cerebellum to the
intracranial volume. The CVF is analogous to the brain
parenchymal fraction, which was previously defined based on a
different segmentation technique [28]. We also normalized
individual brain structure volumes in the same fashion.
One of the sources of inconsistent results in previous studies is
different segmentation methods [17]. We therefore performed a
separate analysis of our data using FSL’s software tools (http://
fmrib.oxo.ax.uk/fsl), which are commonly used to measure brain
volumes in MS [28,29]. We could not directly use SIENAX [30],
FSL’s tool for cross-sectional analysis of brain volumes in the
brain, since its skull-stripping step performed poorly on our data.
We therefore used the skull-stripping tool in the TOADS-
CRUISE package to extract the brain, as described above, and
provided the results to FSL’s FAST algorithm [31] (the same
segmentation tool used in SIENAX) for tissue classification. We
also used the lesion masks generated by Lesion-TOADS to remove
the lesions prior to final segmentation, as lesions can result in
misclassifications within FAST; SIENAX uses the same approach
to handle the lesions. The only major difference between our
approach for using FSL’s FAST for brain tissue classification and
SIENAX is that SIENAX performs normalization to a common
space.
Statistical analysis
We performed the statistical analysis in R (version 2.14.1).
Except for lesion volume, for which we applied a log transform,
each of the structure volume distributions was not significantly
different from Gaussian (Lilliefors test). We therefore assessed the
significance of differences in structure volumes between the MS
and healthy-volunteer groups with multivariable linear regression
models accounting for sex and age. We also performed a partial
correlation analysis to investigate the associations between
impairment measures and structure volumes. To study the effect
of sex on the interaction between disability and atrophy, we ran a
Table 1. Cohort demographic data.
Impairment measure All RRMS SPMS PPMS
EDSS 2.7 (0–6.5)
a 2.0 (0–6.0)
a 6.0 (2.5–6.0)
a 3.7 (2.5–6.5)
a
MSSS 4.2 (0.1–9.1)
a 3.7 (0.1–8.6)
a 5.4 (2.0–6.5)
a 6.9 (2.7–9.1)
a
MSFC 0 (0.7)
b 0.1 (0.7)
b 20.3 (0.4)
b 20.4 (0.7)
b
25-foot walk test (seconds) 4.6 (4.0–5.5)
c 4.4 (3.9–4.9)
c 5.9 (5.3–6.2)
c 7.1 (4.4–10.2)
c
9-hole peg test (seconds) 21.0 (19.4–24.1)
c 20.0 (19.2–22.3)
c 22.3 (20.1–29.2)
c 24.8 (21.2–25.5)
c
PASAT-3, max=60 50 (43–57)
c 51 (41–56)
c 46 (43–56)
c 52 (47–60)
c
vibration sensation
* 4.4 (1.5–16.4)
c 2.2 (1.3–5.6)
c 9.8 (6.0–21.0)
c 18.4 (15.5–44.0)
c
ankle strength measure
(pounds)
42.2 (35.1–52.7)
c 44.5 (40.0–54.0)
c 35.5 (28.2–44.4)
c 32.5 (26.0–42.2)
c
amedian (range),
bmean z-score (standard deviation),
cmedian (interquartile range).
*Vibration units are amplitudes, proportional to the square of the applied voltage.
Abbreviations. RRMS, relapsing remitting multiple sclerosis. SPMS, secondary progressive multiple sclerosis. PPMS, primary progressive multiple sclerosis. CIS, clinically
isolated syndrome. EDSS, Expanded Disability Status Scale. MSSS, Multiple Sclerosis Severity Score. MSFC, Multiple Sclerosis Functional Composite. PASAT-3, Paced
Auditory Serial-Addition Task, 3 second version.
doi:10.1371/journal.pone.0037049.t001
Figure 1. Lesion-TOADS segmentation results. Representative slices from the T1-weighted (A) and FLAIR (B) scans of one of the MS cases.
Lesions are depicted in red (C). 3D rendering of ventricles (blue), putamen (green), caudate (orange), thalamus (pink), brainstem (yellow), and lesions
(red), generated by Lesion-TOADS (D).
doi:10.1371/journal.pone.0037049.g001
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structure volumes.
We used linear regression to investigate the effect of the two
different FLAIR slice thicknesses on the structure and lesion
volumes; we did not find any significant association, so FLAIR
resolution was not included as a covariate in our analysis. Because
this was an exploratory study applying a new segmentation
method, and because brain structure volumes tend to be correlated
with one another (see Table 2), we did not apply a strict correction
for multiple comparisons and instead set the threshold significance
level to a ´ =0.01. Instead, we carefully account for all tests
performed and report p-values so that readers can calibrate
significance relative to Bonferroni corrections.
Results
Brain volume analysis
After additive adjustments for sex and age through a linear
model, all cortical and subcortical GM structure volumes, as well
as CVF, were significantly smaller in the MS cohort (Table 3).
Brainstem volume trended toward smaller values in MS, whereas
ventricle volume trended towards larger values in MS; in fact, the
latter had the largest relative volume change (38% larger in MS).
Total cerebral WM volume, which includes lesion volume as well
as extralesional or ‘‘normal-appearing’’ white matter, was not
significantly reduced in MS (Fig. 2).
Correlation analysis
Lesion volume correlated most strongly with ventricular volume
and CVF but also with caudate and thalamus volumes (Table 2).
Table 4 shows the correlation between each of the impairment
measures and lesion volume, structure volumes, and CVF, all
adjusted for the effects of age and sex. EDSS, MSFC, and 9-hole
peg test time correlated with volumes of WM. 9-hole peg test time
and MSFC also correlated with CVF, ventricle, and thalamus
volumes. Both EDSS and 25-foot walk time correlated with
brainstem volume. 25-foot walk time also correlated with thalamus
volume. Lesion volume only correlated with 9-hole peg test time.
Among the targeted sensorimotor measurements, ankle dorsiflex-
ion strength correlated with thalamus volume and CVF. There
were no correlations between brain structure volumes and great
toe sensation threshold or PASAT-3 score.
In the MS cohort, men scored worse than women on the tests
involving the assessment of physical disability except for ankle
dorsiflexion, where men were stronger; however, only the group
differences for MSSS and ankle dorsiflexion strength were close to
the 0.05 significance level (39% higher MSSS in men; p=0.05 and
30% higher ankle dorsiflexion strength in men; p=0.05). We
therefore further investigated the effect of sex by examining its
interaction with structure volumes. In this analysis, we found a
significant interaction effect in the association of ankle dorsiflexion
strength with cerebral WM volume (p=0.005) and toe sensation
threshold with ventricles volume (p=0.01).
Comparison with an alternative analysis method
We performed a complementary analysis of our data with FSL’s
commonly employed software tools to measure brain volumes. In
this analysis, we used Lesion-TOADS to isolate and remove the
influence of WM lesions on the volume measurements. The FSL-
derived brain-volume results were similar to those obtained with
Lesion-TOADS, showing significant atrophy in GM (6.30% lower
in MS; p,0.001) but not WM (1.09% higher in MS; p=0.14).
However, using FSL’s FAST, none of the impairment measures in
the MS cohort associated with WM or GM volume (Table 5).
Discussion
Brain atrophy is a common feature in MS, a disease that is
otherwise spatially and temporally heterogeneous. We undertook
this work to evaluate brain structure and lesion volumes in a
representative MS cohort at an academic medical center and to
assess the relationships between volumetric abnormalities and
clinical disability. One novel aspect of our study is that we consider
simultaneously a spectrum of disability measures and a wide
palette of brain structures. This analysis allows the findings of
disparate studies on distinct cohorts to be tested in a single group
of MS cases and healthy volunteers. A surprising result of our
study is the finding that the MS cohort had normal WM volume
on average, but that individuals with lower WM volume had more
physical disability. We consider this apparent paradox later in the
Discussion.
Brain atrophy
We found significantly reduced volumes of both cortical and
subcortical GM structures (including thalamus, caudate, and
putamen) in MS cases. Our results also suggest that MS cases have
lower brainstem volume and higher ventricular volume (p=0.02).
We did not find a significant change of the cerebral WM volume
Table 2. Partial correlations of normalized brain structure with one another in MS cases.
white matter caudate putamen thalamus brainstem ventricles
white matter
lesions
cortical gray
matter
0.16 (0.23) 0.44 (,0.001) 0.38 (0.002) 0.37 (0.003) 0.18 (0.18) 20.29 (0.02) 0.13 (0.35)
white matter 0.38 (0.002) 0.03 (0.83) 0.60 (,0.001) 0.36 (0.004) 20.67 (,0.001) 20.27 (0.04)
caudate 0.46 (,0.001) 0.52 (,0.001) 0.34 (0.006) 20.61 (,0.001) 20.32 (0.01)
putamen 0.43 (,0.001) 0.24 (0.06) 20.33 (0.009) 20.07 (0.62)
thalamus 0.57 (,0.001) 20.72 (,0.001) 20.36 (0.005)
brainstem 20.44 (,0.001) 20.21 (0.12)
ventricles 0.40 (,0.001)
cerebral volume
fraction
20.45 (,0.001)
Results are adjusted for linear effects of age and sex. The p-values are shown in parentheses, and results with p,0.01 are shown in boldface.
doi:10.1371/journal.pone.0037049.t002
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abnormally high, probably on an ex vacuo basis. As a result, we
found a significant reduction in the cerebral volume fraction (the
ratio of brain parenchymal volume to intracranial capacity), a
measure that is routinely used as a single-time-point estimate of
brain atrophy in cross-sectional MS studies and that is considered
a reasonable marker of neurodegeneration [2,3,5,16,17,34,35].
Whether or not MS is characterized by specific WM atrophy
has been a matter of some debate [13]. Although we did not find
evidence for overall WM volume loss in our cohort, we did find,
surprisingly, that MS patients with less WM volume tend to have
more disability. In GM, on the other hand, we found evidence of
substantial volume loss, extending previous results by focusing on
cortical volume rather than thickness [7,8,12]. (Though volume
and thickness are related quantities, thinning without volume
reduction might occur, for example, in the presence of a more
complex cortical folding pattern. However, we did not find this to
be the case in our cohort.)
Most prior studies of subcortical GM volumes in MS (with one
notable exception; see [12]) have been limited to individual
structures. In our study, we found that all subcortical GM
structures were significantly atrophic in MS. Previous studies have
identified that the thalamus is especially damaged in MS, probably
reflecting its central role at the nexus of brain information
processing. Caudate nucleus atrophy has been found inconsistently
[12], but the 19% reduction we found here is similar to the extent
of caudate atrophy reported in a previous study [10]. We also
found a 9% reduction in putamen volume, confirming previous
results [12].
In evaluating atrophy within and between groups, one should
always consider the effect of variability in the signal intensity of
individual structures, especially at their borders. This is always a
challenge in performing segmentation, regardless of whether the
segmentation procedure is fully automated, semi-automated, or
manual. In addition to variability within the population, there may
be group-level effects due to signal intensity differences, which
Figure 2. Distributions of normalized cortical gray matter (A) and cerebral white matter (B) volumes in healthy volunteers vs. MS cases. White matter
volume is not significantly atrophic in the MS group, whereas cortical GM volume is substantially lower in MS.
doi:10.1371/journal.pone.0037049.g002
Table 3. Normalized brain structure volumes.
HV mean (SD) MS mean (SD) difference p-value
cortical gray matter 0.3324(0.0179) 0.3193 (0.0157) 23.9% 0.01
white matter 0.2670 (0.0175) 0.2625 (0.0169) 21.7% 0.17
caudate 0.0051 (0.0007) 0.0042 (0.0006) 218.8% ,0.001
putamen 0.0064 (0.0006) 0.0059 (0.0006) 28.7% ,0.001
thalamus 0.0082 (0.0007) 0.0073 (0.0009) 210.8% ,0.001
brainstem 0.0129 (0.0012) 0.0122 (0.0011) 25.4% 0.02
ventricles 0.0123 (0.0065) 0.0169 (0.0072) 37.7% 0.02
cerebral volume fraction 0.7536 (0.0209) 0.7368 (0.0263) 22.2% 0.006
Results with p,0.01 are shown in bold face. Abbreviations. HV, healthy volunteers. MS, multiple sclerosis. SD, standard deviation.
doi:10.1371/journal.pone.0037049.t003
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and healthy volunteer groups. The thalamus and its interface with
the internal capsule present particular problems for segmentation
routines. This is because signal intensity on T1-weighted images in
the thalamus can be quite high, probably due to a relatively high
myelin content. In MS, demyelination in the thalamus would
reduce its signal intensity on T1-weighted images, leading to a
more accurate delineation of the thalamus from the adjacent
internal capsule and consequently artifactually higher thalamic
volumes (and lower white matter volumes) compared to healthy
volunteers. Thus, it is possible that thalamic volumes are actually
lower in MS, and white matter volumes higher (and thus even less
different from healthy volunteers), than we report here.
Association between lesion load and brain structure
volumes
WM lesion load correlated most strongly with ventricle volume
(r=0.40, p,0.001) and CVF (r=20.45, p,0.001), confirming
previous findings [5,17,36–38]. Among the GM structures we
studied, caudate and thalamus volumes were correlated with lesion
load. The association between thalamic atrophy and lesion load in
MS is consistent with prior results and might be expected from the
widespread connections between the thalamus and many areas of
WM, where the lesions we detected are located [11]. In our study,
although the association between lesion load and WM volume did
not reach the 0.01 significance level that we set, it showed a trend
toward a negative correlation between the two (r=20.27,
p=0.04). Most previous studies did not find the inverse correlation
between total WM volume and lesion load that we observed
[3,5,39,40]. This finding can be explained by the fact that MS
lesions cause local tissue destruction (demyelination and axonal
loss).
Volumetric correlates of impairment measures
The most unexpected finding in our cohort was an inverse
correlation between physical disability (EDSS and 9-hole peg test
time) and WM volume in the absence of overt WM atrophy on the
whole-group level. This apparent paradox has several possible
explanations. The simplest possibility is that subtle WM atrophy
was in fact present in our cohort but in too limited an extent to
have been detected in our study. The trending inverse correlation
between WM volume and lesion load provides some evidence for
this possibility because it implies that individuals with high lesion
loads are likely to have more WM atrophy. However, this
explanation begs the question of why WM atrophy is so limited
even in the presence of a high lesion load, a question we address in
the next paragraph. A second explanation for the paradox is that
individuals with lower premorbid WM volume are more likely to
suffer disability, though this seems implausible. Finally, from a
technical point of view, it is also possible that although we included
age as a linear covariate in our regression models, subtle age
differences not properly accounted for in the models might have
obscured a difference in WM volume. Consistent with this
possibility are the findings of Bartzokis et al. [41] that WM
volume slightly increases between the second and fifth decades
before starting to decrease, suggesting that linear modeling may be
limited.
However, there is a more interesting and compelling explana-
tion for the dissociation between WM atrophy (absent) and
significant WM correlation with disability (present). If WM
damaged by MS lesions undergoes a process that is associated
with tissue hypertrophy (such as remyelination and gliosis), the
effects on WM volume of tissue damage such as axonal loss and
demyelination might be offset. If the hypertrophy is primarily
associated with tissue repair, so that people with less disability have
a more efficient repair process, the end result would be a near
preservation of total WM volume in those individuals despite a
cohort-wide correlation with disability scores – exactly the
situation we encountered. In other words, the combination of
MS-related tissue damage and repair would essentially induce a
resorting of WM volumes across the population without overt
atrophy. The residual inverse correlation between WM volume
and lesion load would in this scenario reflect failure of the repair
process in some individuals.
Table 4. Partial correlations of impairment measures with normalized structure volumes.
cortical
gray
matter
white
matter caudate putamen thalamus brainstem ventricles
cerebral
volume
fraction
white
matter
lesions
toe
sensation
0.08 (0.59) 20.10 (0.46) 20.05 (0.74) 20.18 (0.20) 20.16 (0.25) 20.24 (0.07) 20.01 (0.97) 20.08 (0.55) 0.19 (0.17)
ankle
dorsiflexion
0.09
(0.54)
0.20
(0.14)
0.14
(0.32)
0.01 (0.92) 0.44
(,0.001)
0.24
(0.07)
20.29
(0.03)
0.33
(0.01)
20.25
(0.07)
EDSS 0.11 (0.40) 20.40 (0.001) 20.02 (0.86) 0.17 (0.20) 20.16 (0.22) 20.34
(0.007)
0.24 (0.06) 20.27 (0.04) 0.06 (0.68)
MSSS 20.10 (0.44) 20.23 (0.07) 20.06 (0.65) 0.05 (0.72) 20.08 (0.55) 20.30 (0.02) 0.16 (0.23) 20.22 (0.09) 0.07 (0.65)
9-hole
peg test
time
0.00 (0.97) 20.45
(,0.001)
20.20 (0.12) 0.01 (0.97) 20.35 (0.005) 20.27 (0.03) 0.47
(,0.001)
20.46
(,0.001)
0.34 (0.008)
25-foot
walk time
20.01 (0.95) 20.23 (0.08) 20.03 (0.84) 20.04 (0.75) 20.32 (0.01) 20.32
(0.01)
0.23 (0.07) 20.22 (0.10) 0.06 (0.67)
PASAT-3 0.07 (0.61) 0.10 (0.45) 20.04 (0.75) 0.09 (0.48) 0.11 (0.42) 0.02 (0.88) 20.21 (0.11) 0.17 (0.21) 0.15 (0.28)
MSFC 0.05 (0.70) 0.35 (0.005) 0.07 (0.59) 0.05 (0.69) 0.34 (0.007) 0.25 (0.05) 20.42
(0.001)
0.39
(0.001)
20.11 (0.41)
Results are adjusted for linear effects of age and sex. The p-values are shown in parentheses, and results with p,0.01 are shown in boldface. Abbreviations. EDSS,
Expanded Disability Status Scale. MSSS, MS Severity Score. MSFC, Multiple Sclerosis Functional Composite z-score. PASAT-3, Paced Auditory Serial Addition Test, 3-second
version.
doi:10.1371/journal.pone.0037049.t004
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association between GM volume (either total, cortical, or
subcortical) and EDSS; this finding contrasts with some previous
results [2,17,18,42], though not with all [43]. In addition to EDSS,
the 25-foot walk and 9-hole peg test times have previously been
reported to be associated with GM but not WM volume in RRMS
[17,18]. The lack of association between cortical GM atrophy and
impairment measures in our data might be due to the fact that
overall evaluation of cortical GM volume, particularly with respect
to the cortex, blurs regional associations with performance on each
of the examined tasks. If this is the case, a more detailed analysis of
cortical regions would reveal some associations.
Despite the lack of association between cortical GM and
disability in our study, we found out that thalamus volume is
inversely associated with ankle dorsiflexion strength, 9-hole peg
test time, and 25-foot walk time. Thalamic atrophy has been
widely studied in MS, most commonly in the context of cognitive
impairment [11,44]. Our results point to a more complex effect of
thalamic atrophy in MS, specifically in the context of motor
disability. This fits with published reports that although thalamus
is not involved in generating motor function, it is highly involved
in motor control [45].
Similar to the report in [19], our study also revealed that
physical disability (including EDSS and 25-foot walk time) is
correlated with reduced brainstem volume. MSSS and 9-hole peg
test time also showed borderline associations with brainstem
atrophy. These associations can be understood in terms of the
major role played by the brainstem, a mixed GM and WM
structure containing many long tracts that travel in close proximity
to one another, in physical functioning. Our results suggest that
brainstem atrophy might be a candidate marker of physical
disability in MS and are concordant with findings from another
report that studied volume loss in the medulla oblongata [21]. As
suggested by the authors of that study, some of the spinal-cord
damage that is strongly associated with physical disability might be
captured in measures of brainstem volume.
Despite its association with motor dysfunction, brainstem
volume was not significantly correlated with sensory abnormalities
(r=20.24, p=0.07). This is surprising because the WM fibers that
mediate vibration sensation are located in the dorsal columns of
the spinal cord and pass through the brainstem en route to the
thalamus [26]. Sensory abnormalities were also not associated with
supratentorial brain volumes, including the thalamus.
Due to time limitations, our evaluation of cognitive dysfunction
in MS was unfortunately limited to the PASAT-3, and we did not
observe correlations between scores on that test and any of our
volumetric measurements. This includes the thalamus, the volume
of which has been correlated with PASAT-3 scores in other studies
[11,44]. It is important to mention here that the cohorts
investigated in those studies had substantially lower PASAT scores
(35614 in [11] and 42616 in [44]) than our cohort (4969).
Noting that the amount of thalamic atrophy reported by
Houtchens et al. is higher than what we reported here (17% vs.
11%), one might conclude that such an association exists when the
cognitive impairment is more severe. However, a more thorough
investigation of the relationship between brain atrophy and
cognitive disability in MS is necessary to confirm this hypothesis.
Finally, we investigated whether sex plays an important role in
mediating the correlations between brain volumes and impairment
by including interaction terms in our regression models. The
analysis uncovered significant interaction effects in a few cases, but
not across the board. Some of these interactions may be explained
by unbalanced levels of disability across the sexes in our cohort
(disability was generally worse among men), but it is also possible
that the implications of brain structure atrophy may be different in
men and women.
Segmentation and lesion classification
Lesion-TOADS has two major advantages over methods used
in previous studies to perform segmentation and classification of
brain structures in MS. First, unlike tissue classification tools such
as SPM (http://fil.ion.ucl.ac.uk/spm) and FSL’s FAST, SIENA,
and SIENAX, which only yield CSF, GM, and WM volumes,
Lesion-TOADS provides a more detailed subsegmentation for
each tissue. Second, neither these methods nor Freesurfer (http://
surfer.nmr.mgh.harvard.edu), which is commonly used for brain
substructure and cortical segmentation, nor FSL’s FIRST (FSL’s
tool for segmentation of brain substructures), delineates MS lesions
as part of the segmentation process. This commonly results in
misclassifications, since lesions are often segmented as GM. In all
these methods, a separate lesion delineation step, often performed
manually or semi-automatically, is required to correct the problem
[17,46]. Lesion-TOADS addresses this issue without any manual
interaction.
The results of the analysis with FSL’s segmentation tool are
different from our results in some important respects. Both
approaches confirmed that GM is atrophic in MS, whereas WM
does not appear to be. However, the results of the correlation
analysis are different. This difference could be as a result of several
factors. First, it has been shown recently that even by masking out
the lesions prior to SIENAX segmentation, the computed volumes
for GM and WM are not accurate, and a more involved correction
procedure is required [47]. Second, the segmentation of the
subcortical GM structures with the FSL’s FAST tissue segmenta-
tion tool is not as accurate as its segmentation of cortical GM.
Atlas-based approaches such as Lesion-TOADS or FSL’s FIRST
are necessary for accurate segmentation of subcortical GM.
Finally, the difference between the results from the two analyses
could also be due to the grouping of all structures in FAST, which
can cloud the individual effects we captured in Lesion-TOADS.
Limitations and future directions
All studies of structure volume alteration in disease states are
limited by disease-induced changes in MR properties. This results
in signal intensity differences that may bias the tissue segmentation
Table 5. Partial correlations of impairment measures with
normalized structure volumes computed by FSL FAST
segmentation tool.
gray matter white matter
toe sensation 20.08 (0.55) 0.01 (0.92)
ankle dorsiflexion 0.21 (0.11) 0.00 (0.96)
EDSS 20.15 (0.27) 20.08 (0.53)
MSSS 20.25 (0.05) 20.08 (0.56)
9-hole peg test time 20.26 (0.05) 20.14 (0.29)
25-foot walk time 20.16 (0.24) 20.10 (0.43)
PASAT-3 0.06 (0.67) 20.02 (0.89)
MSFC z-score 0.23(0.08) 0.10 (0.45)
Results are adjusted for linear effects of age and sex. The p-values are shown in
parentheses, and results with p,0.01 are shown in boldface. Abbreviations.
EDSS, Expanded Disability Status Scale. MSSS, MS Severity Score. MSFC, Multiple
Sclerosis Functional Composite. PASAT-3, Paced Auditory Serial Addition Test, 3-
second version.
doi:10.1371/journal.pone.0037049.t005
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signal intensity. Thus, common changes in MS, such as T1
prolongation in GM, WM lesions, and normal-appearing WM,
may either accentuate or diminish some of the apparent group
differences. Clearly, a more thorough analysis of these effects,
which would require extensive simulation and modeling, is
necessary.
Lesion-TOADS does not currently segment the globus pallidus.
Due to poor contrast between the globus pallidus and adjacent
WM on T1-weighted images in both healthy volunteers and MS
cases, it is usually included as part of WM in our results. We are
currently working on segmenting this structure as part of a future
release of the software. Nevertheless, as several studies have
reported atrophy of the globus pallidus in MS [12,44], including
the globus pallidus with WM in our analysis cannot explain the
lack of WM atrophy.
Additionally, although a cross-sectional analysis of a represen-
tative MS cohort, such as the one described here, can offer
important insights into the spectrum of disability and brain volume
derangements, only a longitudinal study can truly characterize
brain structure atrophy and lesion accumulation within individuals
[19]. Such a study would also address the confounding factor of
brain volume variability even among healthy individuals, a factor
that is far from completely controlled by normalizing to the
intracranial capacity or including age in the regression analysis.
Longitudinal studies are difficult because of issues related to
participant retention and accumulation of non-MS pathology over
time, and perhaps most importantly variability related to scanner
hardware and software changes. However, it is likely that most or
all of these problems can be satisfactorily overcome.
Finally, quantitative MR measures such as T1 and T2
relaxation times, magnetization transfer ratio (MTR), and
diffusion-derived quantities provide valuable information about
disease burden that is not fully captured in brain structure volumes
[48]. We are working toward combining these quantitative MR
measures with our volumetric analysis in the future.
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